Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers.
The immune defect in hemodialysis (HD) patients is associated with a monocyte dysfunction, including an increase in the production of proinflammatory cytokines. Blood membrane contact leads to an increase in cellular activation and sequestration into the capillary bed of the lung. The influence of the sequestration on the number of mature monocytes was studied by analyzing the fate of monocytes, particularly, the CD14+CD16+ subpopulation, during HD treatment. In thirty stable HD patients, the distinct cell populations were determined by differential blood counts and flow cytometry. Patients with diabetes or systemic vasculitis, those showing evidence of infectious complications or malignancy, or those taking immunosuppressive medications were excluded from the study. Cells from this study population were analyzed before the start, 30 min thereafter, and at the end of HD treatment, each time using a different dialyzer: hemophan, methylmethacrylate (PMMA), triacetate membrane, cuprophane/vitamin E, acrylonitrile, and sodium methallylsulfonate polymer (AN69). The CD14+CD16+ subset decreased at 30 min and remained suppressed for the course of dialysis. To examine whether currently used biocompatible membranes differ in their effect on the sequestration of monocyte subpopulations, temporal monocytic changes were comparatively analyzed during HD with a different dialyzer. The drop in the first 30 min until the end of HD treatment was significant (p<0.05), very uniform, and sharp in all patients, and was independent upon membrane type. The CD14+CD16+ monocyte subpopulation showed increased and longer margination from the blood circulation during HD. Given the fact that CD14+CD16+ monocytes represent a sensitive marker for inflammation or cellular activation, the depletion of these cells may offer an easily accessible parameter that is more sensitive than complement activation for biocompatibility studies on forthcoming, improved dialyzer membranes.
Griveas
Ioannis
I
Nephrology Department, Papageorgiou General Hospital, Thessaloniki, Greece. giannisgriv@hotmail.com
Visvardis
George
G
Sakellariou
George
G
Passadakis
Ploumis
P
Thodis
Ilias
I
Vargemezis
Vasilios
V
Pavlitou
Aikaterini
A
Fleva
Aleka
A
D000368:Aged; D001672:Biocompatible Materials / Q000145:classification / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008422:Materials Testing; D008567:Membranes, Artificial; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D017452:Receptors, IgG / Q000097:blood*; D006435:Renal Dialysis / Q000009:adverse effects / Q000295:instrumentation*
D001672:Biocompatible Materials; D018950:Lipopolysaccharide Receptors; D008567:Membranes, Artificial; D017452:Receptors, IgG